Caffeine 250mg/2ml / Sodium benzoate 250mg/2ml solution for injection vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Caffeine + Sodium benzoate on the MHRA register
Caffeine and Sodium benzoate 500mg/2ml solution for injection vials
Caffeine and Sodium Benzoate 500mg/2ml solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 2 · 1968–2026
Showing the 50 most relevant studies, sorted by most relevant.
Wu W, Chen Z, Zhou H, et al.
2024
- Caffeine
- Capsules
- Physical Endurance
This study aimed to explore the effects of acute ingestion of caffeine capsules on muscle strength and muscle endurance. We searched the PubMed, Web of Science, Cochrane, Scopus, and EBSCO databases. Data were pooled using the weighted mean difference (WMD) and 95% confidence interval. Fourteen studies fulfilled the inclusion criteria. The acute ingestion of caffeine capsules significantly improved muscle strength (WMD, 7.09, p p p p p p p p < 0.00001). An acute ingestion of caffeine capsules significantly improved muscle strength and muscle endurance in the upper body and lower body of males.
Abstract licence: CC BY
da Silva Neves L, de Mattos GVRM, Oliveira-Nazareth Y, et al.
2025
- Caffeine
- Depression
- Anxiety
Anxiety and depression are the most prevalent mental illnesses in the contemporary world. Several animal models have been developed to understand the cellular and molecular mechanisms underlying these disorders and the effect of drugs in modulating the associated behavioral responses. Neuroinflammation has been related to mood disorders. Caffeine is a psychoactive substance that acts as a nonspecific blocker of adenosine receptors. Adenosine receptors are present in neurons and glial cells in different brain areas that are involved in controlling anxiety and depression. However, depending on the context, caffeine can exacerbate or inhibit neuroinflammation and behavioral responses associated with these conditions. This systematic review aimed to evaluate the effects of caffeine and related xanthines on neuroinflammation observed in rodent models of anxiety and depression. A systematic database search (PROSPERO CRD42024517989) returned 17 eligible studies, separated based on the animal model. Most of the analyzed studies revealed that caffeine led to a beneficial effect, mitigating anxiety and depressive-like behaviors and possible cognitive impairments induced by stress. In addition, it also reversed oxidative damage and neuroinflammation by reducing levels of pro-inflammatory cytokines such as IL-1ß, TNF-alpha, and IL-6 and inhibiting glial cell activation. Together, these data reveal a robust effect of caffeine in alleviating symptoms for individuals with these disorders, even though the doses and routes of caffeine administration were highly variable among eligible studies. In addition, they advance the identification of cellular and molecular mechanisms underlying these effects.
Abstract licence: CC BY-NC-ND
Celleno L, Bussoletti C, Tolaini MV, et al.
2025
- Alopecia
- Caffeine
- Sarcosine
Hadavi SMR, Panah A, Shamohammadi S, et al.
2024
- Acetaminophen
- Caffeine
- Anesthesia, Spinal
Costantino A, Maiese A, Lazzari J, et al.
2023
- Energy Drinks
- Drug-Related Side Effects and Adverse Reactions
- Caffeine
In recent years, the consumption of energy drinks by young adults and athletes has risen significantly, but concerns have been raised about the potential health risks associated with excessive consumption. These concerns include cardiovascular problems, nervous system disorders, and the potential for addiction. This review aims to examine the reported effects of acute or chronic abuse of energy drinks on human health. The analysis shows a significant prevalence of adverse effects, particularly on the cardiovascular and neurovegetative systems. In particular, the analysis identified nine cases of cardiac arrest, three of which were fatal. The aetiology of these adverse effects is attributed to the inherent neurostimulant properties of these beverages, of which caffeine is the predominant component. A comparison of documented effects in humans with experimental studies in animal models showed an overlap in results. This review highlights the need for greater rigour in the assessment of sudden cardiac death, particularly in young people, as legal substances such as energy drinks may be involved. We propose stricter limits on the consumption of these beverages than for caffeine, based on the evidence found and the data in the literature. This review also calls for the establishment of regulations governing the consumption of these products in view of their potential impact on human health.
Abstract licence: CC BY
Zduńska A, Cegielska J, Zduński S, et al.
2023
- Caffeine
- Migraine Disorders
- Headache
Consumption of caffeine in the diet, both daily and occasional, has a significant biological effect on the nervous system. Caffeine, through various and not yet fully investigated mechanisms, affects headaches. This is especially noticeable in migraine. In other headaches such as hypnic headache, post-dural puncture headache and spontaneous intracranial hypotension, caffeine is an important therapeutic agent. In turn, abrupt discontinuation of chronically used caffeine can cause caffeine-withdrawal headache. Caffeine can both relieve and trigger headaches.
Abstract licence: CC BY
Dania Mohammed, Hayder Issa
2024
This short overview summarizes sodium benzoate's (SB) dual role as a useful preservative and a possible threat to human and environmental health. This review provides a concise summary of uses, adverse effects, and environmental impact of SB. SB is widely used as a preservative in pharmaceuticals and food products due to its ability to inhibit microbial growth, thus extending the shelf life of various formulations, including syrups and ointments. While generally considered safe, SB can cause allergic reactions and may contribute to conditions like ADHD, particularly in children. It can also disrupt gut microbiota balance. The paper highlights the concerns regarding the environmental persistence of SB. Although it is biodegradable, its degradation rate can vary based on conditions and concentrations. Improper wastewater treatment can lead to its accumulation in aquatic ecosystems, posing risks to both the environment and human health. The review emphasizes the need for awareness regarding the long-term effects of sodium benzoate in ecosystems and suggests that environmentally friendly technologies could mitigate its impact.
Abstract licence: CC BY 4.0
Elhamrawy A, Syed A, Smith T, et al.
2024
Post-dural puncture headache (PDPH) is a common adverse outcome following puncture of the dura. It can occur after inadvertent dural puncture during epidural catheter placement or following diagnostic or therapeutic LP. The incidence of PDPH in pediatric patients has been estimated at 1-15% depending on patient factors (age, gender, body mass index) and needle factors (size and needle bevel/point type). The larger the needle gauge, the higher the incidence of PDPH. Various options have been proposed to treat PDPH including observation, bed rest, hydration, caffeine, and epidural blood/saline patch. The current manuscript provides a review of the use of epidural blood/saline patch in pediatric-aged patients with PDPH.
Abstract licence: CC BY-NC
N. Zengin, D. Yüzbaşıoğlu, F. Ünal, et al.
Food and Chemical Toxicology, 2011
S. Bellet, A. Kershbaum, E. M. Finck
Metabolism: clinical and experimental, 1968
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.